{"id":"measles-mumps-rubella","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Fever"},{"rate":"5","effect":"Rash"},{"rate":"20-30","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"1","effect":"Parotitis"},{"rate":"0.3-3","effect":"Arthralgia/arthritis"}]},"_chembl":{"chemblId":"CHEMBL2109210","moleculeType":"Protein"},"_fixedAt":"2026-03-30T17:17:47.826822","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains live weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease. This triggers both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and rapidly neutralize wild-type viruses upon future exposure. Protection is typically long-lasting and often lifelong.","oneSentence":"The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:02.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles"},{"name":"Prevention of mumps"},{"name":"Prevention of rubella"}]},"_fixedFields":["pubmed(2290)"],"trialDetails":[{"nctId":"NCT06257212","phase":"PHASE4","title":"Live Vaccines and Innate Immune Training in COPD.","status":"COMPLETED","sponsor":"Josefin Eklöf","startDate":"2024-02-28","conditions":"Trained Innate Immunity, COPD","enrollment":60},{"nctId":"NCT05923970","phase":"","title":"Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2024-11-09","conditions":"Vaccination Failure, Vaccine Response Impaired","enrollment":200},{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07406360","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-04-13","conditions":"Measles","enrollment":1209},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07338851","phase":"","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","status":"NOT_YET_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2026-01-30","conditions":"Polio, Measles, Rubella","enrollment":600},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT07312604","phase":"NA","title":"A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis","status":"RECRUITING","sponsor":"Abeer Mohamed Abdelaziz Elkholy","startDate":"2025-12-09","conditions":"Tinea Corporis, Tinea Cruris","enrollment":50},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT07195032","phase":"PHASE4","title":"Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients","status":"RECRUITING","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2025-09-11","conditions":"Heart Transplant Infection Prevention","enrollment":60},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06331702","phase":"PHASE4","title":"Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)","status":"COMPLETED","sponsor":"Liaoning Chengda Biotechnology CO., LTD","startDate":"2024-03-02","conditions":"Japanese Encephalitis, Measles, Mumps","enrollment":408},{"nctId":"NCT05630846","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-12-14","conditions":"Measles; Mumps; Rubella; Chickenpox, Measles","enrollment":801},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT06762938","phase":"NA","title":"The Effect of ShotBlocker on Pain and Satisfaction During Measles-Rubella-Mumps Vaccination","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2024-08-01","conditions":"Pain","enrollment":60},{"nctId":"NCT04475081","phase":"PHASE3","title":"Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2020-09-22","conditions":"Sepsis Syndrome","enrollment":50},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT05401448","phase":"EARLY_PHASE1","title":"Non-specific Effects of FLU-MMR Vaccines in Adults","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-06-01","conditions":"COVID-19","enrollment":638},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05758532","phase":"PHASE4","title":"Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children","status":"RECRUITING","sponsor":"Laure Pittet, MD-PhD","startDate":"2023-03-17","conditions":"Respiratory Tract Infections, Infections, Allergy","enrollment":500},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT05894395","phase":"PHASE3","title":"Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2023-12-01","conditions":"Mumps, Measles, Rubella","enrollment":200},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT05161845","phase":"PHASE4","title":"Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2021-12-23","conditions":"Immunotoxicity, Vaccine","enrollment":1068},{"nctId":"NCT05952505","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines","status":"UNKNOWN","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","startDate":"2023-08","conditions":"SARS-CoV-2 Infection, Varicella, Measles","enrollment":540},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05432141","phase":"PHASE4","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-06-13","conditions":"Poliomyelitis","enrollment":3200},{"nctId":"NCT00240916","phase":"","title":"Ontogeny of Measles Immunity in Infants","status":"COMPLETED","sponsor":"Stanford University","startDate":"1993-07","conditions":"Measles","enrollment":750},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT05279248","phase":"PHASE4","title":"The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2021-08-25","conditions":"Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles","enrollment":300},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT01411241","phase":"PHASE3","title":"Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07-18","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":720},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT05254561","phase":"PHASE2, PHASE3","title":"Triple Antigen vs Monoantigen Immunotherapy for Warts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-11-20","conditions":"Triple Intralesional Immunotherapy Combination in Multiple Recalcitrant Warts","enrollment":160},{"nctId":"NCT03780179","phase":"PHASE4","title":"MMR at 6 Months Trial","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-04-15","conditions":"Meales-mumps-rubella Vaccine","enrollment":6540},{"nctId":"NCT05154097","phase":"","title":"Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)","status":"UNKNOWN","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2022-01-04","conditions":"Measles Vaccine","enrollment":190},{"nctId":"NCT04646239","phase":"","title":"Biomarkers of Trained Immunity Following MMR Vaccination","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-12-17","conditions":"Covid19","enrollment":96},{"nctId":"NCT00013871","phase":"NA","title":"Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Measles","enrollment":300},{"nctId":"NCT00257127","phase":"NA","title":"Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":101},{"nctId":"NCT02861586","phase":"PHASE2","title":"Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2016-08-17","conditions":"Chikungunya Virus Infection","enrollment":263},{"nctId":"NCT00000815","phase":"PHASE2","title":"A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Measles","enrollment":270},{"nctId":"NCT00432523","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01-20","conditions":"Measles, Mumps, Varicella","enrollment":752},{"nctId":"NCT00962819","phase":"","title":"Measles, Mumps, and Rubella (MMR) Immunity in College Students","status":"COMPLETED","sponsor":"Sri Edupuganti, MD MPH","startDate":"2010-03","conditions":"Measles, Mumps, Rubella","enrollment":74},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT04364399","phase":"PHASE4","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2020-11-18","conditions":"Mumps","enrollment":920},{"nctId":"NCT04111432","phase":"PHASE4","title":"Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-07-26","conditions":"Hand, Foot and Mouth Disease","enrollment":372},{"nctId":"NCT03101111","phase":"PHASE2","title":"Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2017-08-09","conditions":"Chikungunya","enrollment":34},{"nctId":"NCT04428359","phase":"NA","title":"A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2020-06-01","conditions":"Verruca Viral","enrollment":66},{"nctId":"NCT03239873","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-17","conditions":"Varicella","enrollment":600},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT04357028","phase":"PHASE3","title":"Measles Vaccine in HCW","status":"SUSPENDED","sponsor":"Kasr El Aini Hospital","startDate":"2020-07-13","conditions":"Covid19","enrollment":200},{"nctId":"NCT03820752","phase":"","title":"Vaccination Coverage and Level of Protection in Patients at Risk","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-10","conditions":"Diabetes, Chronic Kidney Disease, Allergy","enrollment":2179},{"nctId":"NCT02880865","phase":"PHASE4","title":"Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2016-10-13","conditions":"Encephalitis, Japanese, Measles, Mumps","enrollment":628},{"nctId":"NCT01770119","phase":"PHASE4","title":"Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients","status":"UNKNOWN","sponsor":"Klara M. Pósfay Barbe","startDate":"2013-04","conditions":"Measles","enrollment":90},{"nctId":"NCT03148990","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2018-11-20","conditions":"Rubella, Measles","enrollment":432},{"nctId":"NCT03183765","phase":"PHASE4","title":"Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts","status":"COMPLETED","sponsor":"Assiut University","startDate":"2017-08-01","conditions":"Common Wart, Plantar Wart","enrollment":48},{"nctId":"NCT01627561","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Infections, Papillomavirus","enrollment":148},{"nctId":"NCT00148941","phase":"PHASE3","title":"Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-06","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":4209},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Rubella, Mumps, Measles","enrollment":1259},{"nctId":"NCT01621802","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-06-21","conditions":"Measles-Mumps-Rubella","enrollment":4011},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT00092430","phase":"PHASE3","title":"Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09-26","conditions":"Measles, Mumps, Rubella","enrollment":1200},{"nctId":"NCT00892775","phase":"PHASE2","title":"Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Measles, Varicella, Mumps","enrollment":501},{"nctId":"NCT00226499","phase":"PHASE3","title":"Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-01","conditions":"Varicella, Chickenpox Vaccines","enrollment":5803},{"nctId":"NCT03368495","phase":"PHASE4","title":"Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines","status":"COMPLETED","sponsor":"Alba Maria Ropero","startDate":"2015-11-23","conditions":"Vaccine Response Impaired","enrollment":851},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT03853785","phase":"PHASE3","title":"Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-02","conditions":"Condylomata Acuminata","enrollment":45},{"nctId":"NCT02687763","phase":"EARLY_PHASE1","title":"Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-12","conditions":"RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE","enrollment":5},{"nctId":"NCT00326183","phase":"PHASE4","title":"Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-26","conditions":"Hepatitis A, Measles, Mumps","enrollment":1800},{"nctId":"NCT03805828","phase":"NA","title":"Effectiveness of Educational Program on Parenting Stress and Coping Mechanism Among Parents of Children With Autism Spectrum Disorder in Amman, Jordan","status":"UNKNOWN","sponsor":"Universiti Putra Malaysia","startDate":"2019-03-01","conditions":"Autism Spectrum Disorder","enrollment":200},{"nctId":"NCT01536405","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-05","conditions":"Measles, Mumps, Rubella","enrollment":1412},{"nctId":"NCT02062502","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-07","conditions":"Varicella","enrollment":611},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT00578175","phase":"PHASE2","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-20","conditions":"Varicella, Rubella, Mumps","enrollment":1851},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175},{"nctId":"NCT00326118","phase":"PHASE3","title":"Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":433},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00871117","phase":"PHASE3","title":"Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-31","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":478},{"nctId":"NCT01506193","phase":"PHASE3","title":"Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02-06","conditions":"Rubella, Varicella, Measles","enrollment":716},{"nctId":"NCT00402831","phase":"PHASE3","title":"ProQuad® Intramuscular vs Subcutaneous","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Measles, Mumps, Rubella","enrollment":405},{"nctId":"NCT00197015","phase":"PHASE3","title":"Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-06","conditions":"Hepatitis A","enrollment":1474},{"nctId":"NCT00969436","phase":"PHASE3","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Varicella, Rubella, Mumps","enrollment":450}],"_emaApprovals":[],"_faersSignals":[{"count":52,"reaction":"PYREXIA"},{"count":30,"reaction":"CONTRAINDICATED PRODUCT ADMINISTERED"},{"count":24,"reaction":"RASH"},{"count":23,"reaction":"MEASLES"},{"count":20,"reaction":"COUGH"},{"count":16,"reaction":"DECREASED APPETITE"},{"count":16,"reaction":"DRUG INEFFECTIVE"},{"count":15,"reaction":"DEPRESSION"},{"count":15,"reaction":"DIARRHOEA"},{"count":15,"reaction":"DRUG INTOLERANCE"}],"_approvalHistory":[],"publicationCount":2290,"recentPublications":[{"date":"2026 Apr 1","pmid":"41874088","title":"Addressing the crises of declining vaccination rates and measles resurgence by promoting health literacy.","journal":"JAAPA : official journal of the American Academy of Physician Assistants"},{"date":"2026 Feb 27","pmid":"41871555","title":"Dose-specific childhood vaccine refusal in Balıkesir, Türkiye (2024): a population-based surveillance analysis.","journal":"The Turkish journal of pediatrics"},{"date":"2026 Mar 20","pmid":"41863912","title":"Sex-based differences in mumps immunity after a third dose of measles-mumps-rubella vaccine.","journal":"Vaccine"},{"date":"2026 Mar 19","pmid":"41863179","title":"Outbreaks due to measles, mumps, rubella and varicella in schools: a systematic review of the literature.","journal":"Vaccine"},{"date":"2026 Apr","pmid":"41847597","title":"Associations of mid-childhood per- and polyfluoroalkyl substances and early childhood metals with mid-childhood antibody titers.","journal":"Environmental epidemiology (Philadelphia, Pa.)"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Measles-Mumps-Rubella","genericName":"Measles-Mumps-Rubella","companyName":"Hospital Clinic of Barcelona","companyId":"hospital-clinic-of-barcelona","modality":"Biologic","firstApprovalDate":"","aiSummary":"The MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens. Used for Prevention of measles, Prevention of mumps, Prevention of rubella.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}